Cargando…
Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11
INTRODUCTION: Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances that have been associated with multiple instances and types of toxicity. Some SCRAs appear to carry a greater toxicological burden than others, or compared to the prototypical cannabis-de...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798004/ https://www.ncbi.nlm.nih.gov/pubmed/36590635 http://dx.doi.org/10.3389/fpsyt.2022.1048836 |
_version_ | 1784860811076829184 |
---|---|
author | Kevin, Richard C. Cairns, Elizabeth A. Boyd, Rochelle Arnold, Jonathon C. Bowen, Michael T. McGregor, Iain S. Banister, Samuel D. |
author_facet | Kevin, Richard C. Cairns, Elizabeth A. Boyd, Rochelle Arnold, Jonathon C. Bowen, Michael T. McGregor, Iain S. Banister, Samuel D. |
author_sort | Kevin, Richard C. |
collection | PubMed |
description | INTRODUCTION: Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances that have been associated with multiple instances and types of toxicity. Some SCRAs appear to carry a greater toxicological burden than others, or compared to the prototypical cannabis-derived agonist Δ(9)-tetrahydrocannabinol (Δ(9)-THC), despite a common primary mechanism of action via cannabinoid 1 (CB1) receptors. “Off-target” (i.e., non-CB1 receptor) effects could underpin this differential toxicity, although there are limited data around the activity of SCRAs at such targets. METHODS: A selection of 7 SCRAs (AMB-FUBINACA, XLR11, PB-22, AKB-48, AB-CHMINICA, CUMYL-PINACA, and 4F-MDMB-BUTINACA), representing several distinct chemotypes and toxicological profiles, underwent a 30 μM single-point screen against 241 G protein-coupled receptor (GPCR) targets in antagonist and agonist mode using a cellular β-arrestin recruitment assay. Strong screening “hits” at specific GPCRs were followed up in detail using concentration-response assays with AMB-FUBINACA, a SCRA with a particularly notable history of toxicological liability. RESULTS: The single-point screen yielded few hits in agonist mode for any compound aside from CB1 and CB2 receptors, but many hits in antagonist mode, including a range of chemokine receptors, the oxytocin receptor, and histamine receptors. Concentration-response experiments showed that AMB-FUBINACA inhibited most off-targets only at the highest 30 μM concentration, with inhibition of only a small subset of targets, including H(1) histamine and α(2B) adrenergic receptors, at lower concentrations (≥1 μM). AMB-FUBINACA also produced concentration-dependent CB1 receptor signaling disruption at concentrations higher than 1 μM, but did not produce overt cytotoxicity beyond CP55,940 or Δ(9)-THC in CB1 expressing cells. DISCUSSION: These results suggest that while some “off-targets” could possibly contribute to the SCRA toxidrome, particularly at high concentrations, CB1-mediated cellular dysfunction provides support for hypotheses concerning on-target, rather than off-target, toxicity. Further investigation of non-GPCR off-targets is warranted. |
format | Online Article Text |
id | pubmed-9798004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97980042022-12-30 Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11 Kevin, Richard C. Cairns, Elizabeth A. Boyd, Rochelle Arnold, Jonathon C. Bowen, Michael T. McGregor, Iain S. Banister, Samuel D. Front Psychiatry Psychiatry INTRODUCTION: Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances that have been associated with multiple instances and types of toxicity. Some SCRAs appear to carry a greater toxicological burden than others, or compared to the prototypical cannabis-derived agonist Δ(9)-tetrahydrocannabinol (Δ(9)-THC), despite a common primary mechanism of action via cannabinoid 1 (CB1) receptors. “Off-target” (i.e., non-CB1 receptor) effects could underpin this differential toxicity, although there are limited data around the activity of SCRAs at such targets. METHODS: A selection of 7 SCRAs (AMB-FUBINACA, XLR11, PB-22, AKB-48, AB-CHMINICA, CUMYL-PINACA, and 4F-MDMB-BUTINACA), representing several distinct chemotypes and toxicological profiles, underwent a 30 μM single-point screen against 241 G protein-coupled receptor (GPCR) targets in antagonist and agonist mode using a cellular β-arrestin recruitment assay. Strong screening “hits” at specific GPCRs were followed up in detail using concentration-response assays with AMB-FUBINACA, a SCRA with a particularly notable history of toxicological liability. RESULTS: The single-point screen yielded few hits in agonist mode for any compound aside from CB1 and CB2 receptors, but many hits in antagonist mode, including a range of chemokine receptors, the oxytocin receptor, and histamine receptors. Concentration-response experiments showed that AMB-FUBINACA inhibited most off-targets only at the highest 30 μM concentration, with inhibition of only a small subset of targets, including H(1) histamine and α(2B) adrenergic receptors, at lower concentrations (≥1 μM). AMB-FUBINACA also produced concentration-dependent CB1 receptor signaling disruption at concentrations higher than 1 μM, but did not produce overt cytotoxicity beyond CP55,940 or Δ(9)-THC in CB1 expressing cells. DISCUSSION: These results suggest that while some “off-targets” could possibly contribute to the SCRA toxidrome, particularly at high concentrations, CB1-mediated cellular dysfunction provides support for hypotheses concerning on-target, rather than off-target, toxicity. Further investigation of non-GPCR off-targets is warranted. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9798004/ /pubmed/36590635 http://dx.doi.org/10.3389/fpsyt.2022.1048836 Text en Copyright © 2022 Kevin, Cairns, Boyd, Arnold, Bowen, McGregor and Banister. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Kevin, Richard C. Cairns, Elizabeth A. Boyd, Rochelle Arnold, Jonathon C. Bowen, Michael T. McGregor, Iain S. Banister, Samuel D. Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11 |
title | Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11 |
title_full | Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11 |
title_fullStr | Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11 |
title_full_unstemmed | Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11 |
title_short | Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11 |
title_sort | off-target pharmacological profiling of synthetic cannabinoid receptor agonists including amb-fubinaca, cumyl-pinaca, pb-22, and xlr-11 |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798004/ https://www.ncbi.nlm.nih.gov/pubmed/36590635 http://dx.doi.org/10.3389/fpsyt.2022.1048836 |
work_keys_str_mv | AT kevinrichardc offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11 AT cairnselizabetha offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11 AT boydrochelle offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11 AT arnoldjonathonc offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11 AT bowenmichaelt offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11 AT mcgregoriains offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11 AT banistersamueld offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11 |